Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2

infection is associated with disease severity and fatal outcome

- 3 Yang Yang†, Chenguang Shen†, Jinxiu Li†, Jing Yuan, Minghui Yang, Fuxiang Wang,
- 4 Guobao Li, Yanjie Li, Li Xing, Ling Peng, Jinli Wei, Mengli Cao, Haixia Zheng,
- 5 Weibo Wu, Rongrong Zou, Delin Li, Zhixiang Xu, Haiyan Wang, Mingxia Zhang,
- 6 Zheng Zhang, Lei Liu*, Yingxia Liu*

1

2

7

12

- 8 Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research
- 9 Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen
- 10 Third People's Hospital, Second Hospital Affiliated to Southern University of Science
- and Technology, Shenzhen, China.
- †These authors contributed equally.
- *email: yingxialiu@hotmail.com; liulei3322@aliyun.com
- The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute
- 17 respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, December
- 18 2019, and continuously poses a serious threat to public health. Our previous study has
- shown that cytokine storm occurred during SARS-CoV-2 infection, while the detailed
- 20 role of cytokines in the disease severity and progression remained unclear due to the
- 21 limited case number. In this study, we examined 48 cytokines in the plasma samples
- from 53 COVID-19 cases, among whom 34 were severe cases, and the others

moderate. Results showed that 14 cytokines were significantly elevated upon admission in COVID-19 cases. Moreover, IP-10, MCP-3, and IL-1ra were significantly higher in severe cases, and highly associated with the PaO₂/FaO₂ and Murray score. Furthermore, the three cytokines were independent predictors for the progression of COVID-19, and the combination of IP-10, MCP-3 and IL-1ra showed the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC) calculations. Serial detection of IP-10, MCP-3 and IL-1ra in 14 severe cases showed that the continuous high levels of these cytokines were associated with disease deterioration and fatal outcome. In conclusion, we report biomarkers that closely associated with disease severity and outcome of COVID-19. These findings add to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, providing novel therapeutic targets and strategy.

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Coronaviruses are the largest known viruses with a single positive-sense genome of about 31Kb which could infect a wide range of different species, and mainly infect respiratory and intestinal tract causing a wide range of symptoms ¹. Six members of coronaviruses that have been found to infect human beings, including HCoV-229E, HCoVOC43, HCoV-NL63, and HCoV-HKU1, Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) ^{1,2}. Until recently, human infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly identified in late December, 2019, in Wuhan, China 3,4. As of Feb. 29, 2020, a total of 79824 Coronavirus Disease 2019 (COVID-19) cases with 2870 fatal cases were reported ⁵. Furthermore, another 53 countries have also reported COVID-19 cases, posing a serious threat of public health ⁶. Studies have revealed that penumonia is the most common complications following SARS-CoV-2 infection, and followed by acute respiratory distress syndrome (ARDS) ^{7,8}. Inflammation is the body's first coordinated line of defense against tissue damage caused by either injury or infection, involving activating both the innate and adaptive immune responses ⁹. However, exuberant immune responses following infection have been described as a cytokine storm, associated with excessive levels of proinflammatory cytokines and widespread tissue damage including ARDS ¹⁰. Cytokine storm has been found during the infection of influenza viruses 11-16 as well as coronavirues ¹⁷⁻²⁴, and contributes to acute lung injury and development of ARDS ². Preliminary studies have shown that SARS-CoV-2 infection triggers cytokine storm, and results in the increase of a variety of cytokine/chemokine ^{25,26}. However, the detailed role of cytokines in diseases severity and progression remains unknown. In this study, we recruited 53 COVID-19 cases with 34 severe cases and 19

moderate cases defined according to China National Health Commission Guidelines

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

for Diagnosis and Treatment of SARS-CoV-2 infection, and analyzed the plasma cytokine/chemokine profile in detail. Most of the severe cases (73.5%) were ≥ 60 years-old, while the moderate cases were mainly in the group of 16-59 years-old (63.2%) (Table S1). The initial symptoms, co-existing chronic medical conditions, intervals of illness onset to admission and antiviral treatment were similar between the two groups. Complications occurred more frequently in the severe cases, including ARDS, respiratory failure, hepatic and renal insufficiency (Table S1). A complete blood count with differential was assessed for each patient either on the date of hospital admission, or at the earliest time-point and thereafter (Table 1). The percentage of lymphocyte (LYM) and neutrophil (NEU) as well as the CD4 and CD8 counts were significantly lower in the severe cases, indicating a possible dysfunction of immune responses. Then the expression profile of cytokines/chemokines of COVID-19 cases upon admission was analyzed. Elevated concentrations of both pro- and anti-inflammatory cytokines were observed in these cases including IFN-y (interferon, IFN), IL-1ra (interleukin, IL), IL-2ra, IL-6, IL-10, IL-18, HGF (hepatocyte growth factor), MCP-3 (monocyte chemotactic protein-3), MIG (monokine induced gamma interferon), M-CSF (macrophage colony stimulating factor), G-CSF (granulocyte colony-stimulating factor), MIG-1a (macrophage inflammatory protein 1 alpha) CTACK (cutaneous T-cell-attracting chemokine) and IP-10 (interferon gamma induced protein 10), when compared with healthy control, indicating that cytokine storm occurred following SARS-CoV-2 infection (Figure 1) as previously reported ^{3,25}. Similar phenomenon was also observed in SARS-CoV 17-21 and MERS-CoV 22-24 infected patients, despite that the expression profiles were virus specific. Meanwhile,

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

we compared the plasma cytokine/chemokine levels collected from severe and moderate cases at different days after illness onset (d.a.o). The results showed that most of the cytokines were comparable between the two groups and maintained high level even at the later stage of the disease (≥ 15 d.a.o). However, IP-10, MCP-3, IL-1ra and MIG were significantly higher in samples from severe cases in all the three groups of sample collection time, even though statistical significance was not observed in IL-1ra and MIG. Notably, IP-10 in the severe cases possessed a high and similar expression level at all groups of sample collection time. On the contrary, IP-10 in moderate cases was significantly lower and further decreased a lot at ≥ 15 d.a.o. Moreover, comparison of these fourteen cytokines between the severe and moderate cases showed significantly higher levels of IP-10, MCP-3 and IL-1ra in the severe cases (Figure 1). Spearman rank coefficient correlation analysis showed that IP-10, MCP-3 and IL-1ra expression levels were highly correlated with PaO₂/FaO₂ and Murray scores. Interestingly, the viral load (displayed as Ct values) showed obvious correlation with only IP-10, while not MCP-3 and IL-1ra, as well as the PaO₂/FaO₂ and Murray scores (Figure S2). Our previous study has found that the viral shedding in COVID-19 cases is complicated and the viral loads obtained from the regularly used upper respiratory specimens might not consistent with the real case, especially for the severe cases ²⁷. Meanwhile, the main distribution of viruses in the severe and moderate cases were also different, which might influence the induction of cytokines as well. Indeed, studies have found that high viral loads in some types of viral infections correlated with severe diseases ²⁸⁻³⁰, while not for all of them ³¹. These results suggested that the production of specific cytokines while not the viral burden might play central in the pathogenesis COVID-19.

We further analyzed whether these cytokines could be used as predictors for the

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

disease severity and progression of COVID-19. Firstly, we calculated the receiver operating characteristic (ROC) of each single cytokine using the expression levels upon admission. Results showed that the area under the curve (AUC) of the ROC was 0.915, 0.765 and 0.792 for IP-10, MCP-3 and IL-1ra, respectively (Figure 3). Then we tested the different combination of these cytokines for the prediction of disease progression. Combinations of the three cytokines showed the highest AUC of 0.943, followed by the combination of IP-10 and MCP-3 (0.927) as well as the combination of IP-10 and IL-1ra (0.923) (Figure 3). Furthermore, we analyzed the serial change of the three cytokines in 14 severe cases. In the two fatal cases (cases 1 and 2), the expression levels were significantly high upon admission and maintained high levels during the disease progression. Meanwhile, five cases (cases 7~9, 11 and 13) with continuously high levels of these cytokines, especially IP-10 and MCP-3, were still in critical condition. On the contrary, cases 3~6, 10, 12 and 14 with lower levels or significantly decreased levels of these cytokines showed an obvious improvement of the disease, and became moderate cases (cases 4, 10, 12 and 14) or discharged from hospital (cases 3, 5, 6 and 10). These results indicated that these three cytokines could be considered as biomarkers to predict disease progression and outcome of SARS-CoV-2 infections. Cytokine storm with uncontrolled proinflammatory responses induce significant immunopathology and severe disease outcomes during some viral infections, indicating an important role in the pathogenesis of these viruses ^{2,32}. Accordingly, not only the pathogens but also the pathogen induced cytokine storm should be considered during the treatment. Therapy strategy with a combination of antimicrobial and immunotherapy may produce a more favorable outcome ⁹. Corticosteroids which could downregulate proinflammatory cytokine transcription and subsequently inhibit

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

the cytokine storm 33 , and the antiviral cytokine interferon- α were widely used during the treatment of COVID-19 8,34. However, use of high-dose corticosteroids has been shown to be associated with an increase in mortality and significantly longer durations of viral shedding in H7N9 infected patients ³⁵, which is of concern. The results of our study suggested a crucial role of IP-10 in the pathogenesis of SARS-CoV-2, which has also been shown to be associated with disease severity of H5N1, H1N1, SARS-CoV and MERS-CoV ^{16,24,29,36}. A recent study has found that IP-10 (CXCL10)-CXCR3 signaling appears to be a critical factor for the exacerbation of the pathology of ARDS ³⁷. Thus, modulators such as antibody targeting IP-10 might be a promising therapeutic strategy in the treatment of the acute phase of ARDS to ameliorates acute lung injury as shown in H1N1 mouse model ^{37,38}. In summary, we compared the differences of cytokines profiles between severe and moderate COVID-19 cases, and found that IP-10, MCP-3 and IL-1ra were significantly associated with disease severity and progression of COVID-19. Our results added to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and suggest a novel therapeutic strategy using modulators or antibodies against theses cytokines, especially IP-10.

METHODS

Patient information and data collection

Subjects presented in this study were hospitalized COVID-19 patients (N=53), among whom 34 were defined as severe cases according to China National Health Commission Guidelines for Diagnosis and Treatment of 2019-nCoV infection. Healthy controls (N=8) were also included. Clinical information and laboratory result were collected at the earliest time-point after hospitalization. The study protocol was approved by the Ethics Committees of Shenzhen Third People's Hospital (SZTHEC2016001). Informed consents were obtained from all patients or patients family members. The study was conducted in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki and institutional ethics guidelines.

Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)

qRT-PCR were done as previously reported ^{26,34}. In brief, throat swabs, nasal swabs, sputum and BALF specimens were collected from laboratory-confirmed COVID-19 cases upon admission and thereafter. Viral RNAs were extracted from clinical specimens using the QIAamp RNA Viral Kit (Qiagen, Heiden, Germany). A China Food and Drug Administration (CDFA) approved commercially kit (GeneoDX Co., Shanghai, China) were used for the detection of SARS-CoV-2 specific RNAs. Samples with a cycle threshold (Ct) value ≤ 37.0 were considered putatively positive. Samples whose Ct was higher than 37 were re-tested and considered positive if Ct was ≥37 but ≤ 40 and negative if viral RNAs were undetectable on the second test.

Disease severity classification

Disease severity classification and Murray Score calculation were evaluated as previously reported ²⁶. Severity of 2019-nCoV infection was graded according to China National Health Commission Guidelines for Diagnosis and Treatment of SARS-CoV-2 infection. Laboratory confirmed patients with fever, respiratory manifestations and radiological findings indicative of pneumonia were considered moderate cases (COVID-19-M). Laboratory confirmed patients who met any of the following were considered to have severe COVID-19 (COVID-19-S): 1) respiratory distraction (respiration rate≥30/min; 2) resting oxygen saturation≤93%, or 3) arterial oxygen partial pressure (PaO₂) / fraction of inspired oxygen (FiO₂) ≤300 mmHg (1 mmHg = 0.133 kPa). Laboratory confirmed patients who had any of the following were considered in critical condition: 1) respiratory failure requiring mechanical ventilation, 2) shock, or 3) failure of other organs requiring intensive care unit (ICU).

Quantification of hypoxia and Murray Score

The partial pressure of oxygen (PaO₂) in arterial blood taken from the patients at various time-points after hospitalization is measured by the ABL90 blood gas analyzer (Radiometer). The fraction of inspired oxygen (FiO₂) is calculated by the following formula: $FiO_2 = (21 + \text{oxygen flow (in units of l/min)} \times 4) /100$. The PaO_2/FiO_2 ratio (in units of mmHg) is calculated by dividing the PaO_2 value with the FiO_2 value. A PaO_2/FiO_2 ratio less than or equal to 100 mmHg is considered one of the criteria for severe acute respiratory distress syndrome (ARDS). Murray Score were calculated as reported ³⁹.

Cytokine and chemokine measurements

The plasma of patients with laboratory-confirmed COVID-19 cases (N=53) were

collected at the earliest possible time-point after hospitalization and thereafter. The plasma of healthy subjects (N=8) were included as the negative control group. The concentrations of 48 cytokines and chemokines were measured using Bio-Plex Pro Human Cytokine Screening Panel (Bio-Rad) as previously reported ^{15,26}.

Statistical analysis

Fisher exact test was used to compare the indicated rates between the moderate and severe cases. Mann-Whitney U test was used to compare plasma cytokine levels between two groups. The Spearman rank correlation coefficient was used for linear correlation analysis between the expression level of plasma cytokine and PaO2/FiO2 ratio, Murray score as well as viral loads of COVID-19 cases. The area under the receiver operating characteristic (ROC) curve (AUC) of plasma cytokine levels was estimated for the moderate and severe cases. All statistical tests were calculated using SPSS 20.0 for Windows (IBM, Chicago, USA). *P value* less than 0.05 was considered statistically significant.

References

- 214 1 Su, S. et al. Epidemiology, Genetic Recombination, and Pathogenesis of
- 215 Coronaviruses. Trends Microbiol 24, 490-502, doi:10.1016/j.tim.2016.03.003
- 216 (2016).
- 217 Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections:
- causes and consequences of cytokine storm and immunopathology. Semin
- *Immunopathol* **39**, 529-539, doi:10.1007/s00281-017-0629-x (2017).
- Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China,
- 2019. N Engl J Med, doi:10.1056/NEJMoa2001017 (2020).
- 222 4 Wenjie, T. et al. A Novel Coronavirus Genome Identified in a Cluster of
- Pneumonia Cases Wuhan, China 2019–2020. China CDC Weekly 2, 61-62
- 224 (2020).
- 225 5 China, N. H. C. o. t. P. s. R. o. Daily briefing on novel coronavirus cases in
- 226 *China*, <<u>http://en.nhc.gov.cn/2020-02/05/c_76219.htm</u>> (2020).
- 227 6 WHO. Novel Coronavirus (COVID-19) situation,
- 228 < https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125
- 229 cd > (2020).
- 230 7 Wang, D. et al. Clinical Characteristics of 138 Hospitalized Patients With
- 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Jama*,
- doi:10.1001/jama.2020.1585 (2020).
- 8 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in
- 234 China. *N Engl J Med*, doi:10.1056/NEJMoa2002032 (2020).
- 235 9 D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C.
- Targeting the "cytokine storm" for therapeutic benefit. Clin Vaccine Immunol
- **20**, 319-327, doi:10.1128/cvi.00636-12 (2013).
- Ben Salem, C. Acute Respiratory Distress Syndrome. N Engl J Med 377, 1904,
- doi:10.1056/NEJMc1711824 (2017).
- 240 11 Zeng, H. et al. A(H7N9) virus results in early induction of proinflammatory
- 241 cytokine responses in both human lung epithelial and endothelial cells and
- shows increased human adaptation compared with avian H5N1 virus. J Virol
- **89**, 4655-4667, doi:10.1128/jvi.03095-14 (2015).

- 244 12 Guo, J. et al. The Serum Profile of Hypercytokinemia Factors Identified in
- 245 H7N9-Infected Patients can Predict Fatal Outcomes. Sci Rep 5, 10942,
- doi:10.1038/srep10942 (2015).
- 247 13 Zhou, J. et al. Biological features of novel avian influenza A (H7N9) virus.
- 248 *Nature* **499**, 500-503, doi:10.1038/nature12379 (2013).
- 249 14 Yang, Y. et al. Comparison between human infections caused by highly and
- low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and
- virological findings. J Infect 78, 241-248, doi:10.1016/j.jinf.2019.01.005
- 252 (2019).
- 253 15 Bi, Y. et al. Clinical and immunological characteristics of human infections
- with H5N6 avian influenza virus. Clin Infect Dis, doi:10.1093/cid/ciy681
- 255 (2018).
- 256 16 Wang, S. et al. Influenza virus-cytokine-protease cycle in the pathogenesis of
- vascular hyperpermeability in severe influenza. J Infect Dis 202, 991-1001,
- doi:10.1086/656044 (2010).
- 259 Jiang, Y. et al. Characterization of cytokine/chemokine profiles of severe acute
- respiratory syndrome. Am J Respir Crit Care Med 171, 850-857,
- doi:10.1164/rccm.200407-857OC (2005).
- Huang, K. J. et al. An interferon-gamma-related cytokine storm in SARS
- patients. J Med Virol 75, 185-194, doi:10.1002/jmv.20255 (2005).
- 264 19 Zhang, Y. et al. Analysis of serum cytokines in patients with severe acute
- respiratory syndrome. *Infect Immun* 72, 4410-4415,
- doi:10.1128/iai.72.8.4410-4415.2004 (2004).
- 267 20 Wong, C. K. et al. Plasma inflammatory cytokines and chemokines in severe
- acute respiratory syndrome. Clin Exp Immunol 136, 95-103,
- doi:10.1111/j.1365-2249.2004.02415.x (2004).
- 270 21 Dynamic changes in blood cytokine levels as clinical indicators in severe
- acute respiratory syndrome. *Chin Med J (Engl)* **116**, 1283-1287 (2003).
- 272 22 Mubarak, A., Alturaiki, W. & Hemida, M. G. Middle East Respiratory
- Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response,
- and Vaccine Development. J Immunol Res 2019, 6491738,
- 275 doi:10.1155/2019/6491738 (2019).

- 276 23 Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman,
- B. A. MERS-CoV infection in humans is associated with a pro-inflammatory
- Th1 and Th17 cytokine profile. Cytokine 104, 8-13,
- 279 doi:10.1016/j.cyto.2018.01.025 (2018).
- Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients:
- can we go from bench to bedside? PLoS One 9, e88716,
- doi:10.1371/journal.pone.0088716 (2014).
- 283 25 Huang, C. et al. Clinical features of patients infected with 2019 novel
- coronavirus in Wuhan, China. Lancet 395, 497-506,
- doi:10.1016/s0140-6736(20)30183-5 (2020).
- 286 26 Liu;, Y. et al. 2019-novel coronavirus (2019-nCoV) infections trigger an
- exaggerated cytokine response aggravating lung injury. *ChinaXiv* (2020).
- 288 27 Yang, Y. et al. Laboratory diagnosis and monitoring the viral shedding of
- 289 2019-nCoV infections. *medRxiv* (2020).
- 290 28 Ng, K. T. et al. Viral Load and Sequence Analysis Reveal the Symptom
- 291 Severity, Diversity, and Transmission Clusters of Rhinovirus Infections. *Clin*
- 292 *Infect Dis* **67**, 261-268, doi:10.1093/cid/ciy063 (2018).
- 293 29 de Jong, M. D. et al. Fatal outcome of human influenza A (H5N1) is
- associated with high viral load and hypercytokinemia. *Nat Med* **12**, 1203-1207,
- 295 doi:10.1038/nm1477 (2006).
- de La Vega, M. A. et al. Ebola viral load at diagnosis associates with patient
- outcome and outbreak evolution. J Clin Invest 125, 4421-4428,
- 298 doi:10.1172/jci83162 (2015).
- 299 31 Garcia-Maurino, C. et al. Viral Load Dynamics and Clinical Disease Severity
- in Infants With Respiratory Syncytial Virus Infection. J Infect Dis 219,
- 301 1207-1215, doi:10.1093/infdis/jiy655 (2019).
- 302 32 Guo, X. J. & Thomas, P. G. New fronts emerge in the influenza cytokine storm.
- *Semin Immunopathol* **39**, 541-550, doi:10.1007/s00281-017-0636-y (2017).
- 304 33 Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids--new
- mechanisms for old drugs. N Engl J Med 353, 1711-1723,
- 306 doi:10.1056/NEJMra050541 (2005).
- 307 34 Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected

- 308 patients linked to viral loads and lung injury. Sci China Life Sci, 309 doi:10.1007/s11427-020-1643-8 (2020). 310 35 Cao, B. et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral 44, e318-328, 311 Pneumonia. Crit Care Med 312 doi:10.1097/ccm.0000000000001616 (2016). 313 36 Peiris, J. S. et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617-619, doi:10.1016/s0140-6736(04)15595-5 (2004). 314 37 315 Ichikawa, A. et al. CXCL10-CXCR3 enhances the development of 316 neutrophil-mediated fulminant lung injury of viral and nonviral origin. Am J 317 Respir Crit Care Med 187, 65-77, doi:10.1164/rccm.201203-0508OC (2013). 38 Wang, W. et al. Monoclonal antibody against CXCL-10/IP-10 ameliorates 318 319 influenza A (H1N1) virus induced acute lung injury. Cell Res 23, 577-580, 320 doi:10.1038/cr.2013.25 (2013). 321 39 Murray, J. F., Matthay, M. A., Luce, J. M. & Flick, M. R. An expanded 322 definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138, 720-723, doi:10.1164/ajrccm/138.3.720 (1988). 323 324 325 Acknowledgement 326 This work was supported by the National Natural Science Foundation of China (Grant 327 81802004) and the National Science and Technology Major Project (Grants 328 2018ZX10711001, 2017ZX10204401 and 2017ZX10103011), Shenzhen Science and Technology Research and Development Project (Grants JCYJ20180228162201541, 329 330 202002073000001) Sanming Project of Medicine in Shenzhen (SZSM201412003, 331 SZSM201512005). 332 **Author contributions**
- Shen, M. Yang carried out the experiments and analyzed the data. J. Li, J. Yuan, F.

Y. Liu, L. Liu, Z. Zhang and Y. Yang conceived and guided the project. Y. Yang, C.

- Wang, Z. Wang, M. Cao, W. Wu, R. Zou, Y. Li, L. Xing, L. Peng, J. Wei, H. Zheng, Z.
- 336 Xu, and H. Wang collected clinical samples and the data. Y. Yang wrote the
- manuscript. All the authors have read and approved the manuscript.

Competing interests

338

339

The authors declare no competing interests.

Figure legends Figure 1. Comparison of serum cytokine/chemokine concentrations between healthy volunteers and COVID-19 cases. Samples from severe (N=34) and moderate (N=19) COVID-19 cases were collected at the earliest possible time-point after hospitalization for assays measuring the concentrations of 48 cytokines and chemokines, and healthy subjects (N=8) were involved as control. Values were graphed on a logarithmic scale and presented in units of pg/mL. P values between 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were considered statistically significant (*), very significant (**) and extremely significant (***), respectively, whereas ns represents not significant. Figure 2. IP-10, MCP-3 and IL-1ra expression levels were highly correlated with PaO₂/FiO₂ and Murray Score. The expression levels of IP-10, MCP-3 and IL-1ra measured from plasma samples collected upon admission and thereafter and the corresponding PaO2/FiO2 and Murray Score at the same day were analyzed using spearman rank correlation analysis. The *r values* and *p values* were shown. Figure 3. The ROC curve of plasma cytokine levels for patients with mild and severe SARS-CoV-2-infections. The receiver operating characteristic (ROC) curve was calculated using SPSS. The area under the curve (AUC) of ROC for IP-10, MCP-3 and IL-1ra wad estimated using the expression levels upon admission. The P values of all AUC for the three cytokines were less than 0.05.

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

Figure 4. Dynamic changes of IP-10, MCP-10 and IL-1ra in 14 severe cases of **COVID-19 with different outcome and progression.** The expression levels measured at the indicated time-points of 14 severe cases were shown. The fatal cases were marked in red. Cases in critical condition were marked in blue, and the others were cases with moderate disease or discharged at present. Figure S1. Comparison of the significantly elevated cytokines measured at different days post illness onset between severe and moderate COVID-19 cases. The expression levels of 14 significantly elevated cytokines measured at different days post illness onset were shown and compared between the severe and moderate COVID-19 cases. P values between 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were considered statistically significant (*), very significant (**) and extremely significant (***), respectively, whereas ns represents not significant. Figure S2. Correlations between viral load and the cytokines of IP-10, MCP-3 and IL-1ra, as well as PaO2/FiO2 and Murray Score. The correlations between viral load and the cytokines of IP-10, MCP-3 and IL-1ra, as well as PaO2/FiO2 and Murray Score were analyzed using spearman rank correlation analysis. The r values and p values were shown. The viral loads were indicated as Ct values, and lower Ct values represented high viral load.




Figure 1




Figure 2




Figure 3




Figure 4




Figure S1




Figure S2

Table 1. Laboratory results of COVID-19 patients in this study.

Variables†	Total (N=53)	Severe (N=34)	Moderate (N=19)	P values
WBC (× 10 ⁹ /L)	4.52 (3.43-5.89)	4.745 (3.54-5.91)	4.02 (3.42-5.55)	0.5623
LYM (%)	21.6 (15.1-32.1)	20.65(13.13-25.33)	29.40 (19.45-35.05)	0.0288
LYM (× 10^9 /L)	1.12 (0.89-1.48)	1.13 (0.92-1.44)	1.12 (0.89-1.51)	0.7873
NEU (%)	67.4 (57.0-77.4)	69.95 (61.35-79.93)	60.90 (52.95-69.30)	0.0358
NEU (× 10 ⁹ /L)	2.8 (1.81-3.77)	2.98 (2.12-3.7)	2.32 (1.75-4.28)	0.5832
PLT ($\times 10^9$ /L)	171 (138-199)	173(141.5-192)	151 (133-204)	0.6172
AST (U/L)	33 (24-43)	32(22.5.41.5)	33 (24.5-45)	0.8358
ALT (U/L)	26 (16-30)	24.5 (18-29.25)	26 (15-33)	0.5656
TB (umol/L)	9.5 (7.8-12.1)	9.4 (8.10-11.6)	10.3 (6.85-15.35)	0.2973
CRE (µmol/L)	72.7 (54-82)	71.85 (54-80.75)	76 (59-96.5)	0.7739
BUN (mmol/L)	6.68 (3.65-5.59)	5.05 (3.71-5.84)	4.32 (3.57-5.17)	0.0829
CK (U/L)	100 (55.5-126)	83.5(56-126)	100 (55.75-122.5)	0.8519
CK-MB (ng/mL)	0.76 (0.28-1.21)	0.73 (0.28-1.02)	0.89 (0.375-1.775)	0.9289
LDH (U/L)	411.5 (205-530.75)	337(184-525)	432 (223-532)	0.5117
CRP (mg/L)	14.05 (5.7-29.96)	13.33 (5.1-28.28)	15.2 (11.37-32.46)	0.2033
PCT (ng/mL)	0.05 (0.031-0.077)	0.54(0.04-0.08)	0.041 (0.030-0.090)	0.5672
CD4 (count/µl)	362 (217.5-547.25)	329 (200.25-438.5)	559.5(377-784)	0.0027
CD8 (count/µl)	159 (122.5-335)	139 (97-183)	453.5 (232.8-586)	0.0167
CD4/CD8	2.05 (1.3-2.48)	2.26(1.35-2.82)	1.71 (1.21-2.17)	0.1391

[†] Values shown represent the mean and inter-quartile range (IQR).

Table S1. Epidemiological and clinical features of COVID-19 patients in this study.

Characteristics	Total	Severe	Moderate	P values
Character isties	10111	Bevere	Moderate	1 values

	(N=53)	(N=34)	(N=19)	
Median age (range)	62 (51-65)	63.5(42-74)	51 (22-78)	0.0012
Age subgroups	02 (31-03)	03.3(42-74)	31 (22-76)	0.0012
0-15 years	0/53 (0%)	0/26(0%)	0/27 (0%)	1
·	, ,	, ,	, ,	
16-59 years	21/53 (39.6%)	9/34(26.5%)	12/19 (63.2%)	0.0179
≥60 years	32/53 (60.4%)	25/34(73.5%)	7/19 (36.8%)	0.0179
Male (%)	31/53 (58.5%)	22/ 34(64.7%)	9/19 (47.3%)	0.2557
Initial symptoms				
Fever	44/53 (83.0%)	31/34 (91.2%)	13/19 (68.4%)	0.0555
Cough	36/53 (67.9%)	24/34 (70.6%)	12/19 (63.2%)	0.7597
Headache	6/53 (11.3%)	5/34 (14.7%)	1/19(5.3%)	0.4020
Myalgia	28/53 (52.8%)	22/34 (57.7%)	6/19 (48.1%)	0.0254
Chill	6/53 (11.3%)	6/34 (17.6%)	0/19 (0%)	0.0770
Nausea or vomiting	0/53 (0%)	0/34 (0%)	0/19 (0%)	1
Diarrhea	4/53 (7.5%)	4/34 (11.8%)	0/19(0%)	0.2841
Co-existing chronic medical				
conditions				
Chronic heart disease	19/31 (82.6%)	16/24 (65.0%)	3/7 (50%)	0.3839
Chronic lung disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	0.4065
Chronic renal disease	2/31 (6.5%)	2/24 (8.3%)	0/7 (0%)	0.5402
Chronic liver disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	1
Diabetes	6/31 (19.4%)	4/24 (16.7%)	2/7 (28.6%)	0.5959
Cancer	4/31 (12.9%)	2/24 (8.3%)	1/7 (14.3%)	0.5497
Bacterial co-infections	11/53 (20.8%)	8/34(23.5%)	3/19(15.8%)	0.7264
Dacterial co-infections	11/33 (20.8%)	0/34(23.370)	3/17(13.670)	
Interval, median days $(IQR)^+$				
Onset to admission	4 (2, 6)	4 (3, 7)	2 (2, 5)	0.2287
Onset to starting antiviral treatment	4 (3, 7)	4 (4, 7)	4 (2.5, 6.5)	0.9184
Complications				
Pneumonia	53/53 (100%)	34/34 (100%)	19/19 (100%)	1
ARDS	37/53 (71.6%)	33/34 (97.1%)	0/19 (0%)	< 0.0001
Hepatic insufficiency	14/53 (26.4%)	13/34 (38.2%)	1/19 (5.3%)	0.0099
Renal insufficiency	10/53 (18.9%)	10/34 (29.4%)	0/19 (0%)	0.0091
Cardiac failure	3/53 (5.7%)	3/34 (8.8%)	0/27 (0%)	0.5450
Shock	2/53 (3.8%)	2/34 (5.8%)	0/27 (0%)	0.5312
Treatment				
Received antivirals ≤ 2 days after	9/53 (16.9%)	4/34(11.8%)	5/19(26.3%)	0.2550
illness onset	,		, ,	
Received antivirals 3-5 days after	23/53 (43.4%)	14/34(41.2%)	9/19(47.3%)	0.7750
illness onset	,	•	•	
Received antivirals ≥ 6 days after	21/53 (39.6%)	14/34(42.2%)	7/19(36.8%)	0.7794
illness onset	, ,		•	

Corticosteroid	16/53 (30.2%)	13/34(38.2%)	3/19(15.8%)	0.1226
Mechanical ventilation	25/53 (47.2%)	23/34 (67.7%)	0/19 (0%)	< 0.0001
Invasive mechanical ventilation	9/53 (17.0%)	9/34 (26.5%)	0/19 (0%)	0.0188